Tania Fleitas, medical-oncologist, University Hospital Valencia, Spain

Biography
Medical Oncologist and researcher focused on Gastro-esophageal tumors.
Summary presentation
Gastric cancer is heterogenous and overcoming treatment resistance is a current challenge. HER2 is overexpressed in 10-20% of gastric cancers promoting the growth of cancer cells. Targeted therapies , such as trastuzumab and new agents like trastuzumab deruxtecan, have significantly improved outcomes for patients with this phenotype. The development and integration of HER2-targeted treatments represent a major advancement in the personalized treatment of gastric cancer, offering hope for better management and improved patient prognosis.”